14,845 Shares in iShares Biotechnology ETF (NASDAQ:IBB) Purchased by Pathstone Family Office LLC

Pathstone Family Office LLC acquired a new position in iShares Biotechnology ETF (NASDAQ:IBBFree Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 14,845 shares of the financial services provider’s stock, valued at approximately $1,815,000.

A number of other large investors have also recently made changes to their positions in IBB. Moneta Group Investment Advisors LLC grew its position in shares of iShares Biotechnology ETF by 131,598.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 4,469,845 shares of the financial services provider’s stock worth $586,846,000 after buying an additional 4,466,451 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of iShares Biotechnology ETF by 159.9% in the 1st quarter. JPMorgan Chase & Co. now owns 1,966,359 shares of the financial services provider’s stock worth $253,975,000 after buying an additional 1,209,700 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of iShares Biotechnology ETF by 49.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock worth $204,332,000 after buying an additional 521,820 shares during the last quarter. Citigroup Inc. lifted its stake in shares of iShares Biotechnology ETF by 17.7% in the 2nd quarter. Citigroup Inc. now owns 2,354,882 shares of the financial services provider’s stock valued at $298,976,000 after purchasing an additional 354,350 shares during the period. Finally, ExodusPoint Capital Management LP purchased a new position in shares of iShares Biotechnology ETF in the 2nd quarter valued at approximately $31,285,000. 69.61% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Stock Performance

IBB opened at $134.59 on Friday. The business has a 50 day moving average of $133.65 and a 200-day moving average of $126.65. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $139.49.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 27th. Shareholders of record on Thursday, December 21st were paid a dividend of $0.124 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date of this dividend was Wednesday, December 20th.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.